Analysis of Prazosin in Serum

Application
Clinical Research
Robert Ricker

Prazosin drug is designed as a blocker of alpha-adrenergic receptors. Blocking is selective for alpha-1 receptors and, therefore, reduces sympathetic activity to blood vessels without producing reflex tachycardia. Levels may be monitored to determine physiological levels in the blood stream upon treatment or misuse. On-line sample preparation/concentration using column switching enabled this analysis to be a fast, direct approach. The final analytical separation was performed using a ZORBAX SB-CN column. For details of the column switching technique visit the applications page of the ChromTech Website: http://www.chromtech.se/biotrap

Highlights

• After on-line extraction, prazosin in a 50 µL serum sample was analyzed using a ZORBAX SB-CN column.

• The analyte eluted from the ZORBAX SB-CN column with good peak shape.

• ZORBAX StableBond columns operate optimally and with excellent stability at low pH (e.g., 2.8).

Conditions:
ZORBAX SB-CN, 4.6 x 150 mm, 5µm, Agilent P/N: 883975-905 + guard
Mobile phase: 35% ACN and 2 mM Na octanesulfonate in 116 mM Na phosphate, pH 2.8
F=1.0 mL/min, Det.: Fluorescence, ex = 340 nm, em = 385 nm

Courtesy of ChromTech, Sweden
Robert Ricker is an application chemist based at Agilent Technologies, Wilmington, Delaware.

For more information on our products and services, visit our website at:
www.agilent.com/chem

Copyright© 2002 Agilent Technologies, Inc. All Rights Reserved. Reproduction, adaptation or translation without prior written permission is prohibited, except as allowed under the copyright laws.

For Research Use only. Not for use in diagnostic procedures.

Information is subject to change without notice.

Printed in the USA
April 25, 2002
5988-6400EN